Jounce Therapeutics Inc (NASDAQ:JNCE) CFO Kimberlee C. Drapkin sold 5,267 shares of Jounce Therapeutics stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $25.01, for a total transaction of $131,727.67. Following the sale, the chief financial officer now owns 5,267 shares of the company’s stock, valued at $131,727.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) traded up $2.05 during trading on Monday, hitting $27.01. 363,384 shares of the company’s stock were exchanged, compared to its average volume of 364,864. The firm has a market capitalization of $870.96 and a P/E ratio of -50.02. Jounce Therapeutics Inc has a 1-year low of $11.05 and a 1-year high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Thursday, March 8th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.25. The business had revenue of $13.00 million during the quarter, compared to the consensus estimate of $14.95 million. Jounce Therapeutics had a negative net margin of 22.76% and a negative return on equity of 10.24%. The company’s revenue was down 36.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 earnings per share. analysts expect that Jounce Therapeutics Inc will post -1.3 earnings per share for the current year.
Several institutional investors have recently modified their holdings of JNCE. Wells Fargo & Company MN raised its position in shares of Jounce Therapeutics by 476.1% in the second quarter. Wells Fargo & Company MN now owns 20,970 shares of the company’s stock worth $294,000 after acquiring an additional 17,330 shares during the period. Alliancebernstein L.P. acquired a new position in shares of Jounce Therapeutics in the second quarter worth about $177,000. Teachers Advisors LLC raised its position in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after acquiring an additional 2,347 shares during the period. TIAA CREF Investment Management LLC raised its position in shares of Jounce Therapeutics by 519.7% in the second quarter. TIAA CREF Investment Management LLC now owns 64,532 shares of the company’s stock worth $905,000 after acquiring an additional 54,119 shares during the period. Finally, Nationwide Fund Advisors increased its stake in shares of Jounce Therapeutics by 203.3% during the second quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after purchasing an additional 8,007 shares in the last quarter. Institutional investors and hedge funds own 90.81% of the company’s stock.
WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/03/12/jounce-therapeutics-inc-jnce-cfo-sells-131727-67-in-stock.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.